Clinical Effectiveness of Irbesartan and Irbersartan plus Hydrochlorothiazide in Women with Mild to Moderate Essential Hypertension
Objective: The primary objective of this phase IV, nonblind, multicentre study was to determine the antihypertensive effectiveness of irbesartan alone or combined with hydrochlorothiazide (HCTZ) in women with mild to moderate essential hypertension. A secondary objective was to examine the effects of irbesartan on blood lipid levels.
Methods: 188 female patients (94 premenopausal and 94 postmenopausal) with mild to moderate hypertension [seated diastolic blood pressure (SDBP) 95 to 110mm Hg] participated in the study. A 2-week placebo lead-in period was followed by a 24-week active treatment period. Patients initially received 150mg of oral irbesartan once a day, which was titrated to 300 mg/day after 4 weeks in nonresponders. HCTZ 12.5 mg/day was added to treatment after 8 weeks in patients not responding to irbesartan 300 mg/day. The dose of HCTZ could be increased to 25 mg/day after 12 weeks in nonresponders.
Results: 174 patients completed the study, of whom 172 (98.9%) responded to treatment (SDBP <90mm Hg or a reduction of at least 10mm Hg from baseline in SDBP). Mean seated systolic blood pressure and SDBP reductions at 24 weeks were 28.1 and 20.0mm Hg (p = 0.0001), respectively. 88 patients completed the study with irbesartan 150mg, 42 patients with irbesartan 300mg, 18 patients with irbesartan plus HCTZ 300/12.5mg and 26 patients with irbesartan plus HCTZ 300/25mg; response rates were 100, 97.6, 100 and 96.2%, respectively. Total, low density lipoprotein- and high density lipoprotein-cholesterol blood levels were significantly reduced (p < 0.05), but there were no significant changes in blood triglyceride levels or the results of other clinical laboratory tests. Antihypertensive treatment was well tolerated.
Conclusion: Irbesartan, either alone or combined with HCTZ, showed excellent antihypertensive efficacy with a low incidence of adverse events. Hence, irbesartan appears to be a suitable agent for the treatment of hypertension in women.
KeywordsLosartan Irbesartan HCTZ Moderate Hypertension Plasma Cholesterol Level
This study was supported by Bristol-Myers Squibb, México.
- 2.Delisée C, Schaeffer P, Cazaubon C, et al. Characterization of cardiac angiotensin AT1 receptors by [3H]SR 47436. Eur J Pharmacol 1993; 15: 139–44Google Scholar
- 9.Ogira T, Yoshinaga K. The clinical efficacy and tolerability of the angiotensin II-receptor antagonist losartan in Japanese patients with hypertension. Blood Press 1996; 2 Suppl.: 78–81Google Scholar
- 10.Castelli WP. Cardiovascular disease in women. Am J Obstet Gynecol 1990; 158: 1553–60Google Scholar
- 17.Bhattacharyya GK, Johnson RA. Statistical concepts and methods. 2nd ed. Wisconsin (WI): John Wiley and Sons, 1977Google Scholar
- 18.Houston MC, Meador BP, Schipiani LM. Handbook of antihypertensive therapy. 8th ed. Philadelphia (PA): Hanley & Belfus, 1998Google Scholar